Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Foote, J, Lopez-Acevedo, M, Samsa, G, Lee, PS, Kamal, AH, Alvarez Secord, A, and Havrilesky, LJ. "Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 28, no. 2 (February 2018): 302-307.

Full Text

Moss, HA, Havrilesky, LJ, Zafar, SY, Suneja, G, and Chino, J. "Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act." Journal of Oncology Practice 14, no. 2 (February 2018): e92-e102.

Full Text

Billingsley, CC, Cohn, DE, Crim, AK, Li, Q, O'Malley, DM, and Havrilesky, LJ. "Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis." Cancer Treatment and Research Communications 14 (January 2018): 21-25.

Full Text

Moss, HA, and Havrilesky, LJ. "The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care." Gynecologic Oncology 148, no. 1 (January 2018): 12-18. (Review)

Full Text

Foote, J, Secord, AA, Liang, M, Cohn, DE, Jewell, E, and Havrilesky, LJ. "ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer." Journal of Oncology Practice 13, no. 12 (December 2017): e1030-e1039.

Full Text

Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002.

Full Text

Tanner, E, Puechl, A, Levinson, K, Havrilesky, LJ, Sinno, A, Secord, AA, Fader, AN, and Lee, PS. "Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer." Gynecologic Oncology 147, no. 3 (December 2017): 535-540.

Full Text

Gamble, C, Havrilesky, LJ, Myers, ER, Chino, JP, Hollenbeck, S, Plichta, JK, Kelly Marcom, P, Shelley Hwang, E, Kauff, ND, and Greenup, RA. "Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer." Annals of Surgical Oncology 24, no. 11 (October 2017): 3116-3123.

Full Text

Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic Oncology 147, no. 1 (October 2017): 98-103.

Full Text

Bateman, NW, Dubil, EA, Wang, G, Hood, BL, Oliver, JM, Litzi, TA, Gist, GD, Mitchell, DA, Blanton, B, Phippen, NT, Tian, C, Zahn, CM, Cohn, DE, Havrilesky, LJ, Berchuck, A, Shriver, CD, Darcy, KM, Hamilton, CA, Conrads, TP, and Maxwell, GL. "Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients." Cancer 123, no. 20 (October 2017): 4004-4012.

Full Text

Pages